Advanced search
Publication Cover
Therapeutic Delivery Volume 2, 2011 - Issue 10
Submit an article Journal homepage
276
Views
1
CrossRef citations to date
0
Altmetric
Review

Pulmonary Delivery of Inhalable Nanoparticles: Dry Powder Inhalers

MHD Kamal Al-Hallak1 Faculty of Pharmacy and Pharmaceutical Sciences University of AlbertaEdmontonABT6G 2N8Canada;2 Faculty of Pharmacy Damascus UniversityDamascusSyrian Arab Republic
,
Muhammad Khan Sarfraz1 Faculty of Pharmacy and Pharmaceutical Sciences University of AlbertaEdmontonABT6G 2N8Canada;3 Faculty of Pharmacy and Alternative Medicine The Islamia University of BahawalpurBahawalpurPakistan
,
Shirzad Azarmi1 Faculty of Pharmacy and Pharmaceutical Sciences University of AlbertaEdmontonABT6G 2N8Canada;4 Research Center for Pharmaceutical Nanotechnology Faculty of Pharmacy Tabriz University of Medical SciencesTabrizIran
,
Wilson H Roa5 Department of Oncology Cross Cancer Institute University of Alberta 11560 University AvenueEdmontonABT6G 1Z2Canada
,
Warren H Finlay6 Department of Mechanical Engineering University of AlbertaEdmontonABT6G 2G8Canada
&
Raimar Löbenberg1 Faculty of Pharmacy and Pharmaceutical Sciences University of AlbertaEdmontonABT6G 2N8Canada;7 [email protected]
Pages 1313-1324 | Published online: 13 Oct 2011

Bibliography

  • Davis ME , ChenZG, ShinDM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov.7(9), 771–782 (2008).
  • Fukami T , IshiiT, IoTet al. Nanoparticle processing in the solid state dramatically increases the cell membrane permeation of a cholesterol-lowering drug, probucol. Mol. Pharm. 6(3), 1029–1035 (2009).
  • Khan JA , KainthanRK, GanguliM, KizhakkedathuJN, SinghY, MaitiS. Water soluble nanoparticles from PEG-based cationic hyperbranched polymer and RNA that protect RNA from enzymatic degradation. Biomacromolecules7(5), 1386–1388 (2006).
  • Wong HL , BendayanR, RauthAM, XueHY, BabakhanianK, WuXY. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer–lipid hybrid nanoparticle system. J. Pharmacol. Exp. Ther.317(3), 1372–1381 (2006).
  • Brannon-Peppas L , BlanchetteJO. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev.56(11), 1649–1659 (2004).
  • Gipps EM , GroscurthP, KreuterJ, SpeiserPP. Distribution of polyhexylcyanoacrylate nanoparticles in nude mice over extended times and after repeated injection. J. Pharm. Sci.77(3), 208–209 (1988).
  • Moghimi SM , HunterAC, MurrayJC. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev.53(2), 283–318 (2001).
  • Calvo P , Vila-JatoJL, AlonsoMJ. Comparative in vitro evaluation of several colloidal systems, nanoparticles, nanocapsules, and nanoemulsions, as ocular drug carriers. J. Pharm. Sci.85(5), 530–536 (1996).
  • Cosco D , CeliaC, CilurzoF, TrapassoE, PaolinoD. Colloidal carriers for the enhanced delivery through the skin. Expert Opin. Drug Deliv.5(7), 737–755 (2008).
  • Azarmi S , RoaWH, LobenbergR. Targeted delivery of nanoparticles for the treatment of lung diseases. Adv. Drug Deliv. Rev.60(8), 863–875 (2008).
  • Al-Hallak KM , AzarmiS, Anwar-MohamedA, RoaWH, LobenbergR. Secondary cytotoxicity mediated by alveolar macrophages: a contribution to the total efficacy of nanoparticles in lung cancer therapy? Eur. J. Pharm. Biopharm.76(1), 112–119 (2010).
  • Chow AH , TongHH, ChattopadhyayP, ShekunovBY. Particle engineering for pulmonary drug delivery. Pharm. Res.24(3), 411–437 (2007).
  • Dailey LA , SchmehlT, GesslerTet al. Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. J. Control. Release 86(1), 131–144 (2003).
  • Shrewsbury SB , BoscoAP, UsterPS. Pharmacokinetics of a novel submicron budesonide dispersion for nebulized delivery in asthma. Int. J. Pharm.365(1–2), 12–17 (2009).
  • Pandey R , SharmaA, ZahoorA, SharmaS, Khuller Gk, Prasad B. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug-delivery system for experimental tuberculosis. J. Antimicrob. Chemother.52(6), 981–986 (2003).
  • Ostrander KD , BoschHW, BondanzaDM. An in-vitro assessment of a NanoCrystal beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization. Eur. J. Pharm. Biopharm.48(3), 207–215 (1999).
  • Rance RW . Studies of the factors controlling the action of hair sprays: III. The influence of particle velocity and diameter on the capture of particles by arrays of hair fiber. J. Soc. Cosm. Chem.25, 545–561 (1974).
  • Timsina MP , MartinGP, MarriottC, GandertonD, YianneskiM. Drug delivery to the respiratory tract using dry powder inhalers. Int. J. Pharm.101, 1–13 (1994).
  • Crompton GK . Dry powder inhalers: advantages and limitations. J. Aerosol Med.4(3), 151–156 (1991).
  • Finlay WH . The Mechanics of Inhaled Pharmaceutical Aerosols: an Introduction. Academic Press, London, UK (2001).
  • Atkins PJ . Dry powder inhalers: an overview. Respir. Care50(10), 1304–1312 (2005).
  • Vidgren MT , KarkkainenA, KarjalainenP, NuutinenJ, ParonenTP. In vitro and in vivo deposition of drug particles inhaled from pressurised aerosol and dry powder inhaler. Drug Dev. Ind. Pharm.14, 2649–2665 (1988).
  • Edwards DA , HanesJ, CaponettiGet al. Large porous particles for pulmonary drug delivery. Science 276(5320), 1868–1871 (1997).
  • Sung JC , PulliamBL, EdwardsDA. Nanoparticles for drug delivery to the lungs. Trends Biotechnol.25(12), 563–570 (2007).
  • Cheow WS , ChangMW, HadinotoK. Antibacterial efficacy of inhalable levofloxacin-loaded polymeric nanoparticles against E. coli biofilm cells: the effect of antibiotic release profile. Pharm. Res.27(8), 1597–1609 (2010).
  • Suk JS , LaiSK, BoylanNJ, DawsonMR, BoyleMP, HanesJ. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine. Nanomedicine (Lond)6(2), 365–375 (2011).
  • Roa WH , AzarmiS, Al-HallakMH, FinlayWH, MaglioccoAM, LobenbergR. Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. J. Control. Release150(1), 49–55 (2011).
  • Takashima Y , SaitoR, NakajimaAet al. Spray-drying preparation of microparticles containing cationic PLGA nanospheres as gene carriers for avoiding aggregation of nanospheres. Int. J. Pharm. 343(1–2), 262–269 (2007).
  • Sharma A , SharmaS, KhullerGK. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J. Antimicrob. Chemother.54(4), 761–766 (2004).
  • Davda J , LabhasetwarV. Characterization of nanoparticle uptake by endothelial cells. Int. J. Pharm.233(1–2), 51–59 (2002).
  • Al-Hallak MH , SarfrazMK, AzarmiS, KohanMH, RoaWH, LobenbergR. Microcalorimetric method to assess phagocytosis: macrophage–nanoparticle interactions. AAPS J.13(1), 20–29 (2010).
  • Muttil P , PregoC, Garcia-ContrerasLet al. Immunization of guinea pigs with novel hepatitis B antigen as nanoparticle aggregate powders administered by the pulmonary route. AAPS J. 12(3), 330–337 (2010).
  • Muttil P , PulliamB, Garcia-ContrerasLet al. Pulmonary immunization of guinea pigs with diphtheria CRM-197 antigen as nanoparticle aggregate dry powders enhance local and systemic immune responses. AAPS J. 12(4), 699–707 (2010).
  • Sung J c, Padilla DJ, Garcia-Contreras L et al. Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery. Pharm. Res.26(8), 1847–1855 (2009).
  • Bruinenberg P , BlanchardJD, CipollaD, DaytonF, MudumbaS, GondaI. Inhaled liposomal ciprofloxacin: once a day management of respiratory infections. Respiratory Drug Delivery1, 73–82 (2010).
  • Cipolla D , RedelmeierT, EastmanS, BruinenbergP, GondaI. Liposomes, niosomes and proniosomes – a critical update of their (commercial) development as inhaled products. Respiratory Drug Delivery1, 41–54 (2011).
  • Carvalho TC , PetersJI, WilliamsRO 3rd. Influence of particle size on regional lung deposition – what evidence is there? Int. J. Pharm.406(1–2), 1–10 (2011).
  • Tsapis N , BennettD, JacksonB, WeitzDA, EdwardsDA. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc. Natl Acad. Sci. USA99(19), 12001–12005 (2002).
  • Kabbaj M , PhillipsNC. Anticancer activity of mycobacterial DNA: effect of formulation as chitosan nanoparticles. J. Drug Target9(5), 317–328 (2001).
  • Pilcer G , AmighiK. Formulation strategy and use of excipients in pulmonary drug delivery. Int. J. Pharm.392(1–2), 1–19 (2010).
  • Hinds WC . Aerosol Technology: Properties, Behavior and Measurement of Airborne Particles. Wiley-Interscience, NY, USA (1999).
  • Kawakami K , SumitaniC, YoshihashiY, YonemochiE, TeradaK. Investigation of the dynamic process during spray-drying to improve aerodynamic performance of inhalation particles. Int. J. Pharm.390(2), 250–259 (2010).
  • Kho K , CheowWS, LieRH, HadinotoK. Aqueous re-dispersibility of spray-dried antibiotic-loaded polycaprolactone nanoparticle aggregates for inhaled anti-biofilm therapy. Powder Technol.203(3), 432–439 (2010).
  • Hadinoto K , PhanapavudhikulP, KewuZ, TanBHR. Novel formulation of large hollow nanoparticles aggregates as potential carriers in inhaled delivery of nanoparticulate drugs. Ind. Eng. Chem. Res.45, 3697–3706 (2006).
  • Cheow WS , LiS, HadinotoK. Spray drying formulation of hollow spherical aggregates of silica nanoparticles by experimental design. Chem. Eng. Res. Design88, 673–685 (2010).
  • Hadinoto K , PhanapavudhikulP, KewuZ, TanRB. Dry powder aerosol delivery of large hollow nanoparticulate aggregates as prospective carriers of nanoparticulate drugs: effects of phospholipids. Int. J. Pharm.333(1–2), 187–198 (2007).
  • Kho K , HadinotoK. Aqueous re-dispersibility characterization of spray-dried hollow spherical silica nano-aggregates. Powder Tech.198, 354–363 (2010).
  • Hadinoto K , CheowWS. Hollow spherical nanoparticulate aggregates as potential ultrasound contrast agent: shell thickness characterization. Drug. Dev. Ind. Pharm.35(10), 1167–1179 (2009).
  • Kho K , HadinotoK. Effects of excipient formulation on the morphology and aqueous re-dispersibility of dry-powder silica nano-aggregates. Colloids Surf. A Physicochem. Eng. Aspects359, 71–81 (2010).
  • Tomoda K , OhkoshiT, NakajimaT, MakinoK. Preparation and properties of inhalable nanocomposite particles: effects of the size, weight ratio of the primary nanoparticles in nanocomposite particles and temperature at a spray-dryer inlet upon properties of nanocomposite particles. Colloids Surf. B Biointerfaces64(1), 70–76 (2008).
  • Tomoda K , OhkoshiT, KawaiY, NishiwakiM, NakajimaT, MakinoK. Preparation and properties of inhalable nanocomposite particles: effects of the temperature at a spray-dryer inlet upon the properties of particles. Colloids Surf. B Biointerfaces61(2), 138–144 (2008).
  • Yamamoto H , HoshinaW, KurashimaHet al. Engineering of poly(DL-lactic-co-glycolic acid) nanocomposite particles for dry powder inhalation dosage forms of insulin with the spray-fluidized bed granulating system. Advanced Powder Technol. 18(2), 215–228 (2007).
  • Jensen DM , CunD, MaltesenMJ, FrokjaerS, NielsenHM, FogedC. Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. J. Control. Release142(1), 138–145 (2009).
  • Lebhardt T , RoeslerS, UusitaloHP, KisselT. Surfactant-free redispersible nanoparticles in fast-dissolving composite microcarriers for dry-powder inhalation. Eur. J. Pharm. Biopharm.78(1), 90–96 (2011).
  • Wang ZL , FinlayWH, PepplerMS, SweeneyLG. Powder formation by atmospheric spray-freeze-drying. Powder Technol.170(1), 45–52 (2006).
  • Cheow WS , NgML, KhoK, HadinotoK. Spray-freeze-drying production of thermally sensitive polymeric nanoparticle aggregates for inhaled drug delivery: effect of freeze-drying adjuvants. Int. J. Pharm.404(1–2), 289–300 (2010).
  • El-Gendy N , GormanEM, MunsonEJ, BerklandC. Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution. J. Pharm. Sci.98(8), 2731–2746 (2009).
  • El-Gendy N , DesaiV, BerklandC. Agglomerates of ciprofloxacin nanoparticles yield fine dry powder aerosols. J. Pharm. Innov.5, 79–86 (2010).
  • El-Gendy N , BerklandC. Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm. Res.26(7), 1752–1763 (2009).
  • El-Gendy N , Aillon Kl, Berkland C. Dry powdered aerosols of diatrizoic acid nanoparticle agglomerates as a lung contrast agent. Int. J. Pharm.391(1–2), 305–312 (2010).
  • Plumley C , GormanEM, El-GendyN, BybeeCR, MunsonEJ, BerklandC. Nifedipine nanoparticle agglomeration as a dry powder aerosol formulation strategy. Int. J. Pharm.369(1–2), 136–143 (2009).
  • Aillon KL , El-GendyN, DennisC, NorenbergJP, McdonaldJ, BerklandC. Iodinated NanoClusters as an inhaled computed tomography contrast agent for lung visualization. Mol. Pharm.7(4), 1274–1282 (2010).
  • Tomoda K , OhkoshiT, HirotaKet al. Preparation and properties of inhalable nanocomposite particles for treatment of lung cancer. Colloids Surf. B Biointerfaces 71(2), 177–182 (2009).
  • Aillon KL , XieY, El-GendyN, BerklandCJ, ForrestML. Effects of nanomaterial physicochemical properties on in vivo toxicity. Adv. Drug Deliv. Rev.61(6), 457–466 (2009).
  • Mizoe T , OzekiT, OkadaH. Preparation of drug nanoparticle-containing microparticles using a 4-fluid nozzle spray drier for oral, pulmonary, and injection dosage forms. J. Control. Release122(1), 10–15 (2007).
  • Sham JO , ZhangY, FinlayWH, RoaWH, LobenbergR. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. Int. J. Pharm.269(2), 457–467 (2004).
  • Iskandar F , GradonL, OkuyamaK. Control of the morphology of nanostructured particles prepared by the spray drying of a nanoparticle sol. J. Colloid Interface Sci.265(2), 296–303 (2003).
  • Grenha A , SeijoB, Remunan-LopezC. Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J. Pharm. Sci.25(4–5), 427–437 (2005).
  • Grenha A , SeijoB, SerraC, Remunan-LopezC. Chitosan nanoparticle-loaded mannitol microspheres: structure and surface characterization. Biomacromolecules8(7), 2072–2079 (2007).
  • Li X , GuoQ, ZhengXet al. Preparation of honokiol-loaded chitosan microparticles via spray-drying method intended for pulmonary delivery. Drug Deliv. 16(3), 160–166 (2009).
  • Kaye RS , PurewalTS, AlparHO. Simultaneously manufactured nano-in-micro (SIMANIM) particles for dry-powder modified-release delivery of antibodies. J. Pharm. Sci.98(11), 4055–4068 (2009).
  • Ohashi K , KabasawaT, OzekiT, OkadaH. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. J. Control. Release135(1), 19–24 (2009).
  • El-Sherbiny IM , SmythHD. Biodegradable nano-micro carrier systems for sustained pulmonary drug delivery: (I) self-assembled nanoparticles encapsulated in respirable/swellable semi-IPN microspheres. Int. J. Pharm.395(1–2), 132–141 (2010).
  • Azarmi S , LobenbergR, RoaWH, TaiS, FinlayWH. Formulation and in vivo evaluation of effervescent inhalable carrier particles for pulmonary delivery of nanoparticles. Drug Dev. Ind. Pharm.34(9), 943–947 (2008).
  • Niwa T , ShimabaraH, KondoM, DanjoK. Design of porous microparticles with single-micron size by novel spray freeze-drying technique using four-fluid nozzle. Int. J. Pharm.382(1–2), 88–97 (2009).
  • Schiffter H , CondliffeJ, VonhoffS. Spray-freeze-drying of nanosuspensions: the manufacture of insulin particles for needle-free ballistic powder delivery. J. R. Soc. Interface7(4), 483–500 (2010).
  • Abdelwahed W , DegobertG, FessiH. A pilot study of freeze drying of poly(epsilon-caprolactone) nanocapsules stabilized by poly(vinyl alcohol): formulation and process optimization. Int. J. Pharm.309(1–2), 178–188 (2006).
  • Abdelwahed W , DegobertG, StainmesseS, FessiH. Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv. Drug Deliv. Rev.58(15), 1688–1713 (2006).
  • Arnold MM , GormanEM, SchieberLJ, MunsonEJ, BerklandC. NanoCipro encapsulation in monodisperse large porous PLGA microparticles. J. Control. Release121(1–2), 100–109 (2007).
  • Ely L , RoaW, Finlay Wh, Lobenberg R. Effervescent dry powder for respiratory drug delivery. Eur. J. Pharm. Biopharm.65(3), 346–353 (2007).
  • Al-Hallak MH , AzarmiS, SunCet al. Pulmonary toxicity of polysorbate-80-coated inhalable nanoparticles; in vitro and in vivo evaluation. AAPS J. 12(3), 294–299 (2010).
  • Li YZ , SunX, GongT, LiuJ, ZuoJ, ZhangZR. Inhalable microparticles as carriers for pulmonary delivery of thymopentin-loaded solid–lipid nanoparticles. Pharm. Res.27(9), 1977–1986 (2010).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.